Promoter-hypermethylation is causing functional relevant downregulation of methylthioadenosine phosphorylase (MTAP) expression in hepatocellular carcinoma

Carcinogenesis

Volumn 27, Issue 1, 2006, Pages 64-72

  Hellerbrand, Claus ^a   Mühlbauer, Marcus ^a   Wallner, Susanne ^a   Schuierer, Marion ^a   Behrmann, Iris ^b   Bataille, Frauke ^a   Weiss, Thomas ^a   Schölmerich, Jürgen ^a   Bosserhoff, Anja Katrin ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5' METHYLTHIOADENOSINE PHOSPHORYLASE; ALPHA INTERFERON; GAMMA INTERFERON; MESSENGER RNA;

ARTICLE; CANCER INVASION; CELL CLONE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INACTIVATION; GENE LOSS; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METHYLATION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; SENSITIVITY ANALYSIS; TUMOR CELL LINE; WESTERN BLOTTING;

CARCINOMA, HEPATOCELLULAR; CELL MOVEMENT; CELL PROLIFERATION; DNA METHYLATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON TYPE II; INTERFERON-ALPHA; INTERFERON-GAMMA; LIVER; LIVER NEOPLASMS; LUCIFERASES; MUTATION; NEOPLASM INVASIVENESS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); PROMOTER REGIONS, GENETIC; PURINE-NUCLEOSIDE PHOSPHORYLASE; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 29744437726     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgi201     Document Type: Article

References (46)

1. Okuda,K. (2000) Hepatocellular carcinoma. J. Hepatol., 32, 225-237.
2. Schafer,D.F. and Sorrell,M.F. (1999) Hepatocellular carcinoma. Lancet, 353, 1253-1257.
3. Olopade,O.I., Pomykala,H.M., Hagos,F., Sveen,L.W., Espinosa,R.III, Dreyling,M.H., Gursky,S., Stadler,W.M., Le Beau,M.M. and Bohlander,S.K. (1995) Construction of a 2.8-megabase yeast artificial chromosome contig and cloning of the human methylthioadenosine phosphorylase gene from the tumor suppressor region on 9p21. Proc. Natl Acad. Sci. USA, 92, 6489-6493.
4. Christopher,S.A., Diegelman,P., Porter,C.W. and Kruger,W.D. (2002) Methylthioadenosine phosphorylase, a gene frequently codeleted with p16(cdkN2a/ARF), acts as a tumor suppressor in a breast cancer cell line. Cancer Res., 62, 6639-6644.
5. Garcia-Castellano,J.M., Villanueva,A., Healey,J.H., Sowers,R., Cordon-Cardo,C, Huvos,A., Bertino,J.R., Meyers,P. and Gorlick,R. (2002) Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma. Clin. Cancer Res., 8, 782-787.
6. Wong,Y.F., Chung,T.K., Cheung,T.H., Nobori,T. and Chang,A.M. (1998) MTAP gene deletion in endometrial cancer. Gynecol. Obstet. Invest., 45, 272-276.
7. Hori,Y., Hori,H., Yamada, Y., Carrera,C.J., Tomonaga,M., Kamihira,S., Carson,D.A. and Nobori,T. (1998) The methylthioadenosine phosphorylase gene is frequently co-deleted with the p16INK4a gene in acute type adult T-cell leukemia. Int. J. Cancer, 75, 51-56.
8. Kamatani,N. and Carson,D.A. (1980) Abnormal regulation of methylthioadenosine and polyamine metabolism in methylthioadenosine phosphorylase-deficient human leukemic cell lines. Cancer Res., 40, 4178-4182.
9. Bonilla,F., Orlow,I. and Cordon-Cardo,C. (1998) Mutational study of p16CDKN2/MTS1/INK4A and p57KIP2 genes in hepatocellular carcinoma. Int. J. Oncol., 12, 583-588.
10. Biden,K., Young,J., Buttenshaw,R., Searle,J., Cooksley,G., Xu,D.B. and Leggett,B. (1997) Frequency of mutation and deletion of the tumor suppressor gene CDKN2A (MTS1/p16) in hepatocellular carcinoma from an Australian population. Hepatology, 25, 593-597.
11. Lin,Y.W., Chen,C.H., Huang,G.T., Lee,P.H., Wang,J.T., Chen,D.S., Lu,F.J. and Sheu,J.C. (1998) Infrequent mutations and no methylation of CDKN2A (P16/MTS1) and CDKN2B (p15/MTS2) in hepatocellular carcinoma in Taiwan. Eur. J. Cancer, 34, 1789-1795.
12. Thomas,T. and Thomas,T.J. (2003) Polyamine metabolism and cancer. J. Cell. Mol. Med., 7, 113-126.
13. Megosh,L., Gilmour,S.K., Rosson,D., Soler,A.P., Blessing,M., Sawicki,J.A. and O'Brien,T.G. (1995) Increased frequency of spontaneous skin tumors in transgenic mice which overexpress ornithine decarboxylase. Cancer Res., 55, 4205-4209.
14. Auvinen,M., Paasinen,A., Andersson,L.C. and Holtta,E. (1992) Ornithine decarboxylase activity is critical for cell transformation. Nature, 360, 355-358.
15. Gan,F.Y., Gesell,M.S., Alousi,M. and Luk,G.D. (1993) Analysis of ODC and c-myc gene expression in hepatocellular carcinoma by in situ hybridization and immunohistochemistry. J. Histochem. Cytochem., 41, 1185 1196.
16. Kubo,S., Tamori,A., Nishiguchi,S., Omura,T., Kinoshita,H., Hirohashi,K., Kuroki,T. and Otani,S. (1998) Relationship of polyamine metabolism to degree of malignancy of human hepatocellular carcinoma. Oncol. Rep., 5, 1385-1388.
17. Subhi,A.L., Diegelman,P., Porter,C.W., Tang,B., Lu,Z.J., Markham,G.D. and Kruger,W.D. (2003) Methylthioadenosine phosphorylase regulates ornithine decarboxylase by production of downstream metabolites. J. Biol. Chem., 278, 49868-49873.
18. Mowen,K.A., Tang,J., Zhu,W., Schurter,B.T., Shuai,K., Herschman,H.R. and David,M. (2001) Arginine methylation of STAT1 modulates IFNalpha/ beta-induced transcription. Cell, 104, 731-741.
19. Ramana,C.V., Gil,M.P., Schreiber,R.D. and Stark, G.R. (2002) Stat1-dependent and -independent pathways in IFN-gamma-dependent signaling. Trends Immunol., 23, 96-101.
20. Obora,A., Shiratori,Y., Okuno,M., et al. (2002) Synergistic induction of apoptosis by acyclic retinoid and interferon-beta in human hepatocellular carcinoma cells. Hepatology, 36, 1115-1124.
21. Behrmann,I., Wallner,S., Komyod,W., Heinrich,P.C., Schuierer,M., Buettner,R. and Bosserhoff, A.K. (2003) Characterization of methylthioadenosine phosphorylase (MTAP) expression in malignant melanoma. Am. J. Pathol., 163, 683-690.
22. Weiss,T.S., Jahn,B., Cetto,M., Jauch,K.W. and Thasler,W.E. (2002) Collagen sandwich culture affects intracellular polyamine levels of human hepatocytes. Cell. Prolif., 35, 257-267.
23. Poser,I., Dominguez,D., de,Herreros,A.G., Varnai,A., Buettner,R. and Bosserhoff,A.K. (2001) Loss of E-cadherin expression in melanoma cells involves up-regulation of the transcriptional repressor Snail. J. Biol. Chem., 276, 24661-24666.
24. Wong,Y.F., Chung,T.K., Cheung,T.H., Nobori,T. and Chang,A.M. (1998) MTAP gene deletion in endometrial cancer. Gynecol. Obstet. Invest., 45, 272-276.
25. Behrmann,I., Wallner,S., Komyod,W., Heinrich,P.C., Schuierer,M., Buettner,R. and Bosserhoff, A.K. (2003) Characterization of methylthioadenosine phosphorylase (MTAP) expression in malignant melanoma. Am. J. Pathol., 163, 683-690.
26. Rothhammer,T., Hahne,J.C., Florin,A., Poser,I., Soncin,F., Wernert,N. and Bosserhoff, A.K. (2004) The Ets-1 transcription factor is involved in the development and invasion of malignant melanoma. Cell. Mol. Life Sci., 61, 118-128.
27. Berasain,C., Hevia,H., Fernandez-Irigoyen,J., Larrea,E., Caballeria,J., Mato,J.M., Prieto,J., Corrales,F.J., Garcia-Trevijano,E.R. and Avila,M.A. (2004) Methylthioadenosine phosphorylase gene expression is impaired in human liver cirrhosis and hepatocarcinoma. Biochim. Biophys. Acta, 1690, 276-284.
28. Mowen,K.A., Tang,J., Zhu,W., Schurter,B.T., Shuai,K., Herschman,H.R. and David,M. (2001) Arginine methylation of STAT1 modulates IFNalpha/ beta-induced transcription. Cell, 104, 731-741.
29. Thorgeirsson,S.S. and Grisham,J.W. (2002) Molecular pathogenesis of human hepatocellular carcinoma. Nat. Genet., 31, 339-346.
30. Coleman,W.B. (2003) Mechanisms of human hepatocarcinogenesis. Curr. Mol. Med., 3, 573-588.
31. Liew,C.T., Li,H.M., Lo,K.W. et al. (1999) Frequent allelic loss on chromosome 9 in hepatocellular carcinoma. Int. J. Cancer, 81, 319-324.
32. Watanabe,T., Nakamura, M., Yonekawa,Y., Kleihues,P. and Ohgaki,H. (2001) Promoter hypermethylation and homozygous deletion of the p14ARF and p16INK4a genes in oligodendrogliomas. Acta Neuropathol. (Berl), 101, 185-189.
33. Nakamura,M., Watanabe,T., Klangby,U., Asker,C., Wiman,K., Yonekawa,Y., Kleihues,P. and Ohgaki,H. (2001) p14ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol., 11, 159-168.
34. Florl,A.R., Franke,K.H., Niederacher,D., Gerharz,C.D., Seifert,H.H. and Schulz,W.A. (2000) DNA methylation and the mechanisms of CDKN2A inactivation in transitional cell carcinoma of the urinary bladder. Lab. Invest., 80, 1513-1522.
35. Wong,D.J., Barrett,M.T., Stoger,R., Emond,M.J. and Reid,B.J. (1997) p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. Cancer Res., 57, 2619-2622.
36. Yang,B., Guo,M., Herman,J.G. and Clark,D.P. (2003) Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am. J. Pathol., 163, 1101-1107.
37. Christopher,S.A., Diegelman,P., Porter,C.W. and Kruger,W.D. (2002) Methylthioadenosine phosphorylase, a gene frequently codeleted with p16(cdkN2a/ARF), acts as a tumor suppressor in a breast cancer cell line. Cancer Res., 62, 6639-6644.
38. Garcea,R., Pascale,R., Daino,L., Frassetto,S., Cozzolino,P., Ruggiu,M.E., Vannini,M.G., Gaspa,L. and Feo,F. (1987) Variations of ornithine decarboxylase activity and S-adenosyl-L-methionine and 5′-methylthioadenosine contents during the development of diethylnitrosamine-induced liver hyperplastic nodules and hepatocellular carcinoma. Carcinogenesis, 8, 653-658.
39. Spiegel,R.J. (1986) Intron-A (interferon alfa-2b), clinical overview and future directions. Semin. Oncol., 13, 89-101.
40. Kirkwood,J.M., Ibrahim,J.G., Sosman,J.A., Sondak, V.K., Agarwala,S.S., Ernstoff, M.S. and Rao,U. (2001) High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma, results of intergroup trial E1694/S9512/C509801. J. Clin. Oncol., 19, 2370-2380.
41. Kirkwood,J.M., Ibrahim,J.G., Sondak, V.K., Richards,J., Flaherty,L.E., Ernstoff, M.S., Smith,T.J., Rao,U., Steele,M. and Blum,R.H. (2000) High- and low-dose interferon alfa-2b in high-risk melanoma, first analysis of intergroup trial E1690/S9111/C9190. J. Clin. Oncol., 18, 2444-2458.
42. Nakaji,M., Yano,Y., Ninomiya,T., Seo,Y., Hamano,K., Yoon,S., Kasuga, M., Teramoto,T., Hayashi,Y. and Yokozaki,H. (2004) IFN-alpha prevents the growth of pre-neoplastic lesions and inhibits the development of hepatocellular carcinoma in the rat. Carcinogenesis, 25, 389-397.
43. Patt,Y.Z., Hassan,M.M., Lozano,R.D., Brown,T.D., Vauthey,J.N., Curley,S.A. and Ellis,L.M. (2003) Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J. Clin. Oncol., 21, 421-427.
44. Leung,T.W., Patt,Y.Z., Lau,W.Y., Ho,S.K., Yu,S.C., Chan,A.T., Mok,T.S., Yeo,W., Liew,C.T., Leung,N.W., Tang,A.M. and Johnson,P.J. (1999) Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin. Cancer Res., 5, 1676-1681.
45. Reinisch,W., Holub,M., Katz,A. et al. (2002) Prospective pilot study of recombinant granulocyte-macrophage colony-stimulating factor and interferon-gamma in patients with inoperable hepatocellular carcinoma. J. Immunother., 25, 489-499.
46. Yuen,M.F., Hon,C., Hui,C.K., Siu,C.W. and Lai,C.L. (2002) Recombinant interferon alfa 2b therapy in a patient with metastatic hepatocellular carcinoma. J. Clin. Gastroenterol., 35, 272-275.